0A50 Stock Chart & Stats
$1.20
-$0.16(-8.04%)
At close: 4:00 PM EDT
$1.20
-$0.16(-8.04%)
Day’s Range― - ―
52-Week Range$0.92 - $46.17
Previous CloseN/A
Volume30.23K
Average Volume (3M)8.11K
Market Cap
$6.75M
Enterprise Value$11.51
Total Cash (Recent Filing)$3.65M
Total Debt (Recent Filing)$1.80M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Nov 05, 2026EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.72
Shares Outstanding7,141,423
10 Day Avg. Volume9,321
30 Day Avg. Volume8,108
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-12.15
Revenue Forecast (FY)$552.40K
Bulls Say, Bears Say
Bulls Say
Regulatory And Clinical ProgressThe completed analytical and clinical work, followed by a dual FDA submission, advances the Co-Dx platform toward commercialization. Regulatory progress can reduce development uncertainty and create a foundation for recurring assay revenue if authorization and market adoption follow.
International Platform ExpansionInternational commercialization and localized manufacturing initiatives broaden the company’s potential distribution footprint beyond the United States. If execution continues, these partnerships may improve access to regional testing programs and support scalable deployment of instruments, assays and consumables.
Operating Expense DisciplineThe reduction in operating expenses shows management is actively resizing spending while continuing regulatory and product development work. Better cost control can extend the runway available for commercialization and reduce the amount of revenue required to improve future operating leverage.
Bears Say
Collapsed Revenue And Weak MarginsThe severe revenue decline indicates that prior demand has not translated into a durable commercial base. Very low sales combined with weak gross margins leaves fixed development and corporate costs disproportionate to revenue, making a sustained return to profitability dependent on significant growth.
Persistent Cash Burn And Limited LiquidityOngoing operating and free-cash-flow losses are consuming the resources needed to fund clinical, regulatory and commercial programs. The sharp cash decline leaves limited financial runway relative to the burn rate, increasing dependence on additional funding before products generate meaningful sales.
Shrinking Equity Base And Financing DependenceThe erosion of shareholders’ equity reflects the cumulative impact of sustained losses and reduces the company’s financial cushion. Management’s financing review signals that internal cash generation is insufficient, while future equity-linked funding could dilute existing ownership and constrain strategic flexibility.
Co-Diagnostics News
0A50 FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest share price was $0.92 and its highest was $46.17 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $6.75M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 46 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Aug 13, 2026. The company reported -$1.46 earnings per share for the quarter.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -1.25.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 7,141,423 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$1.46 in its last earnings report. Following the earnings report the stock price went up 0.69%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in GB:0A50
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
0A50 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.View all GB:0A50 earnings summaries0A50 Stock 12 Month Forecast
Average Price Target
$4.00
▲(233.33% Upside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―